Continuous Glucose Monitoring as an alternative for Cystic Fibrosis Related diabetes screening and diagnosis

Area of Science:

• Endocrinology
• Metabolic Disorders
• Cystic Fibrosis Research

Background:

• Cystic Fibrosis Related Diabetes (CFRD) diagnosis lacks definitive screening methods.
• Current data on HbA1c and Continuous Glucose Monitoring (CGM) for CFRD detection are uncertain.
• Oral Glucose Tolerance Test (OGTT) is the standard but less preferred diagnostic method.

Purpose of the Study:

• To evaluate the diagnostic capacity of HbA1c, classical CGM indexes, and novel glucodensities CGM metrics for CFRD.
• To compare these methods against OGTT results for CFRD diagnosis.
• To assess patient preferences for CFRD screening methods.

Main Methods:

• Prospective observational study of 38 patients with recent OGTT results.
• 14-day CGM sensor wear for all participants.
• Questionnaire on patient preferences for CFRD screening.

Main Results:

• CGM was better accepted than OGTT; HbA1c preferred for simplicity.
• CGM metrics like time above 180 mg/dL (93% sensitivity) and 140 mg/dL (90% specificity) showed diagnostic potential.
• Glucodensities improved CGM's diagnostic capacity with >85% sensitivity and specificity for CFRD.

Conclusions:

• Glucodensities demonstrate superior discriminatory capacity for early, mild CFRD compared to HbA1c and standard CGM metrics.
• Larger prospective studies are required to validate these findings.
• Further research should define optimal CGM metrics, glucodensities, and preferred screening strategies for CFRD.